Muscarinic M1 receptor sequence: Preliminary studies on its effects on cognition and expression

Schizophrenia Research

Volumn 138, Issue 1, 2012, Pages 94-98

  Scarr, Elizabeth ^a,b   Sundram, Suresh ^a,b,c   Deljo, Azita ^c   Cowie, Tiffany Francis ^b,d   Gibbons, Andrew Stuart ^a,b   Juzva, Susan ^b   Mackinnon, Andrew ^b   Wood, Stephen J ^b,e   Testa, Renee ^b,f   Pantelis, Christos ^b   Dean, Brian ^a,b  

^a FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c Northern Psychiatry Research Centre   (Australia)

^d National Neuroscience Facility Australia   (Australia)

^e UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^f MONASH UNIVERSITY   (Australia)

Author keywords

Executive function; Human; MRNA; Muscarinic M1 receptor (CHRM1); Schizophrenia; Single nucleotide polymorphism

Indexed keywords

MESSENGER RNA; MUSCARINIC M1 RECEPTOR;

ADULT; AMINO ACID SEQUENCE; ARTICLE; COGNITION; COGNITIVE DEFECT; DISEASE SEVERITY; DNA SEQUENCE; EXECUTIVE FUNCTION; FEMALE; GENE SEQUENCE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NATIONAL ADULT READING TEST; NEUROPSYCHOLOGICAL TEST; POSITIVE AND NEGATIVE SYNDROME SCALE; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHIZOPHRENIA; WISCONSIN CARD SORTING TEST;

ADULT; COGNITION DISORDERS; COHORT STUDIES; EXECUTIVE FUNCTION; FEMALE; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, MUSCARINIC; RNA, MESSENGER; SCHIZOPHRENIA;

EID: 84861527018     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2012.02.011     Document Type: Article

References (19)

1. Alvarez J., Emory E. Executive function and the frontal lobes: a meta-analytic review. Neuropsychol. Rev. 2006, 16:17-42.
2. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 1994, American Psychiatric Association, Washington, D.C. 4 edn.
3. Bradley S.R., Lameh J., Ohrmund L., Son T., Bajpai A., Nguyen D., Friberg M., Burstein E.S., Spalding T.A., Ott T.R., Schiffer H.H., Tabatabaei A., McFarland K., Davis R.E., Bonhaus D.W. AC-260584, an orally bioavailable M1 muscarinic receptor allosteric agonist, improves cognitive performance in an animal model. Neuropharmacology 2010, 58:365-373.
4. Dean B. Dissecting the syndrome of schizophrenia: progress toward clinically useful biomarkers. Schizophr. Res. Treat. 2011, Article ID 614730. 10.1155/2011/614730.
5. Goldstein G., Beers S.R., Shemansky W.J. Neuropsychological differences between schizophrenic patients with heterogeneous Wisconsin Card Sorting Test performance. Schizophr. Res. 1996, 21:13-18.
6. Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia?. Am. J. Psychiatry 1996, 153:321-330.
7. Hill C., Keks N., Roberts S., Opeskin K., Dean B., Copolov D. Diagnostic Instrument for Brain Studies 1999, Mental Health Research Institute, Melbourne.
8. Jones C.K., Byun N., Bubser M. Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia. Neuropsychopharmacology 2012, 37:16-42.
9. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13:261-276.
10. Liao D.L., Hong C.J., Chen H.M., Chen Y.E., Lee S.M., Chang C.Y., Chen H., Tsai S.J. Association of muscarinic m1 receptor genetic polymorphisms with psychiatric symptoms and cognitive function in schizophrenic patients. Neuropsychobiology 2003, 48:72-76.
11. Nuechterlein K.H., Barch D.M., Gold J.M., Goldberg T.E., Green M.F., Heaton R.K. Identification of separable cognitive factors in schizophrenia. Schizophr. Res. 2004, 72:29-39.
12. Raedler T.J., Bymaster F.P., Tandon R., Copolov D., Dean B. Towards a muscarinic hypothesis of schizophrenia. Mol. Psychiatry 2006, 12:232-246.
13. Rende B., Ramsberger G., Miyake A. Commonalities and differences in the working memory components underlying letter and category fluency tasks: a dual-task investigation. Neuropsychology 2002, 16:309-321.
14. Roberts S.B., Hill C.A., Dean B., Keks N.A., Opeskin K., Copolov D.L. Confirmation of the diagnosis of schizophrenia after death using DSM- IV: a Victorian experience. Aust. N. Z. J. Psychiatry 1998, 32:73-76.
15. Scarr E., Cowie T.F., Kanellakis S., Sundram S., Pantelis C., Dean B. Decreased cortical muscarinic receptors define a subgroup of subjects with schizophrenia. Mol. Psychiatry 2009, 14:1017-1023.
16. Shekhar A., Potter W.Z., Lightfoot J., Lienemann J., Dube S., Mallinckrodt C., Bymaster F.P., McKinzie D.L., Felder C.C. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am. J. Psychiatry 2008, 165:1033-1039.
17. Shirey J.K., Brady A.E., Jones P.J., Davis A.A., Bridges T.M., Kennedy J.P., Jadhav S.B., Menon U.N., Xiang Z., Watson M.L., Christian E.P., Doherty J.J., Quirk M.C., Snyder D.H., Lah J.J., Levey A.I., Nicolle M.M., Lindsley C.W., Conn P.J. A selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learning. J. Neurosci. 2009, 29:14271-14286.
18. Tandon R., Belmaker R.H., Gattaz W.F., Lopez-Ibor J., Okasha A., Singh B., Stein D.J., Olie J.P., Fleischhacker W.W., Moeller H.J. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr. Res. 2008, 100:20-38.
19. Vanover K.E., Veinbergs I., Davis R.E. Antipsychotic-like behavioral effects and cognitive enhancement by a potent and selective muscarinic M-sub-1 receptor agonist, AC-260584. Behav. Neurosci. 2008, 122:570-575.